Diabetes Mellitus, Nonalcoholic Fatty Liver Disease, and Conjugated Linoleic Acid (Omega 6): What Is the Link?

Hegazy, Maha A.; Elsayed, Naglaa M.; Ali, Hanan Mahmoud; Hassan, H. E.; Rashed, Laila Ahmed

doi:10.1155/2019/5267025

Cited by 20 publications

(11 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The study found that the risk of NAFLD was increased in Type 2 diabetes mellitus, while NAFLD can also be an independent risk factor for the progression of diabetes mellitus [22][23] , thus forming a vicious circle.The speci c prevalence of NAFLD is still unknown, depending on the method used for screening, which is lower when liver transaminase and/or liver ultrasound are used, and higher with gold standard magnetic resonance spectroscopy (MRS). The prevalence of NAFLD in industrialized countries is believed to be between 40% and 50%, and even higher in patients with T2DM, with a prevalence of up to 90% in morbidly obese patients [24][25][26] .…”

Section: Discussionmentioning

confidence: 95%

Potential New Biomarkers Discovery of Early Nonalcoholic Fatty Liver Disease in Human by Liquid Chromatography–Mass Spectrometry

Hu¹,

Wang²,

Zhang³

et al. 2020

Preprint

View full text Add to dashboard Cite

BackgroundNAFLD is a common metabolic disorders disease which influenced 20~30% people. NAFLD can progress to cirrhosis, liver fibrosis and even liver cancer. Liver puncture is the gold standard. However, due to its trauma and possible complications, its clinical use is currently limited. Therefore, it is of great clinical significance and value to find a noninvasive biochemical index that can diagnose NAFLD early.ObjectiveOur aim was to identify the potential biomarkers in NAFLD people in early stage via untargeted metabolomics study.MethodsIn our research, From January to October 2019, 224 patients aged 18-55 were selected from the outpatient department and ward of gastroenterology department of Putuo Hospital in Shanghai.According to the NAFLD diagnostic criteria of the guidelines for diagnosis and treatment of nonalcoholic fatty liver disease (2018) formulated by the National workship on Fatty liver and alcoholic liver disease and Chinese Society on Hepatology, they were divided into the healthy control group and the experimental group.Besides,on the same day, the height, weight, waist, BMI, blood pressure and heart rate of patients were measured, and fasting blood was taken to obtain blood glucose,ALT, AST, TB, DB, TP, ALB, Che, ALP, γ - GT, TG, TC, HDL-C, LDL-C and other serum data.Serum samples were analyzed using LC/MS and data was processed by SIEVE software and simca-P to validate the potential biomarkers. The altered metabolites were identified by variable importance in projection value (VIP > 1) and ANOVA (p<0.01). The pathway analysis was performed by using MetaboAnalyst 4.0. In addition, our project has passed the review of ethics committee of Putuo Hospital Affiliated to Shanghai University of traditional Chinese medicine, and its ethics approval number is ptec-a-2018-49-1.ResultsThe serum biochemical indicators of early NAFLD patients showed no significant difference with NC (p>0.05). While there was significant difference of blood lipids indicators between NAFLD and NC (p<0.001). Finally, 55 metabolites were identified and the AUC of ROC curve results showed that new identified biomarkers owned high predictability and reliability. ConclusionIt is found that 15 metabolites in serum were of great diagnostic value in early NAFLD patients. AUC of these biomarkers (>0.9) were much higher than clinical indicators (0.770). This may be worth further research in the clinic.

show abstract

Section: Discussionmentioning

confidence: 95%

Potential New Biomarkers Discovery of Early Nonalcoholic Fatty Liver Disease in Human by Liquid Chromatography–Mass Spectrometry

Hu¹,

Wang²,

Zhang³

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…The reduction of CLA in NAFLD and diabetic obese patients demonstrated the correlation between CLA and regulation of energy metabolism and maintenance of metabolic homeostasis in the liver [ 71 ]. CLA can also induce significant changes in the fatty acid profile of the liver [ 72 ].…”

Section: Discussionmentioning

confidence: 99%

Conjugated Linoleic Acid Treatment Attenuates Cancerous features in Hepatocellular Carcinoma Cells

Miri-Lavasani

Torabi

Aminian

et al. 2022

Stem Cells International

View full text Add to dashboard Cite

Background. A growing number of hepatocellular carcinoma (HCC), and recurrence frequency recently have drawn researchers’ attention to alternative approaches. The concept of differentiation therapies (DT) relies on inducing differentiation in HCC cells in order to inhibit recurrence and metastasis. Hepatocyte nuclear factor 4 alpha (HNF4α) is the key hepatogenesis transcription factor and its upregulation may decrease the invasiveness of cancerous cells by suppressing epithelial-mesenchymal transition (EMT). This study aimed to evaluate the effect of conjugated linoleic acid (CLA) treatment, natural ligand of HNF4α, on the proliferation, migration, and invasion capacities of HCC cells in vitro. Materials and Method. Sk-Hep-1 and Hep-3B cells were treated with different doses of CLA or BIM5078 [1-(2 ′ -chloro-5 ′ -nitrobenzenesulfonyl)−2-methylbenzimidazole], an HNF4α antagonist. The expression levels of HNF4a and EMT related genes were evaluated and associated to hepatocytic functionalities, migration, and colony formation capacities, as well as to viability and proliferation rate of HCC cells. Results. In both HCC lines, CLA treatment induced HNF4α expression in parallel to significantly decreased EMT marker levels, migration, colony formation capacity, and proliferation rate, whereas BIM5078 treatment resulted in the opposite effects. Moreover, CLA supplementation also upregulated ALB, ZO1, and HNF4α proteins as well as glycogen storage capacity in the treated HCC cells. Conclusion. CLA treatment can induce a remarkable hepatocytic differentiation in HCC cells and attenuates cancerous features. This could be as a result of HNF4a induction and EMT inhibition.

show abstract

“…In the present study 18 (34.62%) had normal BMI, 19 (36.54%) patients were overweight (25-30 Kg/m 2 ) and 15 (28.85%) were Obese (≥ 30 Kg/m 2 ). 6 Kyung-Soo Kim et al(2019), mentioned in his review article that Saroglitazar reduced alkaline phosphatase as well as triglyceride levels. 4 A review article by Kaul et al(2019), also stated that Saroglitazar was found effective in lowering ALT levels and improving fatty liver (evaluated by…”

Section: Discussionmentioning

confidence: 99%

An Investigator Initiated Prospective, Single Arm Observational Study to Evaluate the Safety and Efficacy of Saroglitazar 4 mg in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD)/Non- Alcoholic Steatohepatitis (NASH)

Hajare¹,

Gokak²,

Ghorpade³

et al. 2019

IJCMR

View full text Add to dashboard Cite

Introduction: Saroglitazar is known to safely and effectively improve dyslipidemia by reducing triglyceride (TG), low density lipoprotein (LDL) cholesterol, very low-density lipoprotein (VLDL) cholesterol, non-high-density lipoprotein (non-HDL) cholesterol and increasing high density lipoprotein (HDL) cholesterol. In addition, saroglitazar can improve glycemic indices in diabetic patients by reducing fasting plasma glucose (FPG) and glycosylated haemoglobin (HbA1c). Aim of the study was to evaluate the hospital based clinic-pathological profile, diagnosis, treatment and follow up of Indian patients with Non-alcoholic fatty liver disease and to evaluate the safety and efficacy of Saroglitazar 4 mg in patients with Non-alcoholic fatty liver disease /Non-alcoholic Steatohepatitis in real life setting. Material and methods: This was an ongoing observational study with the sample size of 52 patients having Nonalcoholic fatty liver disease and dyslipidaemia with or without Type 2 Diabetes Mellitus and treatment follow up for a period of 1 year in the Department Of Gastroenterology. The data was collected from eligible patients who have been prescribed Saroglitazar 4 mg once daily in routine clinical practice. Primary endpoints were to see liver stiffness. Secondary endpoints were to measure serum alanine aminotransferase, aspartate aminotransferase level and Serum triglycerides level. Results: There was a significant decrease in Serum alanine aminotransferase (p <0.001), aspartate aminotransferase (p value < 0.001), triglycerides (p value <0.001) and triglycerides (p value 0.01), levels after the treatment as compared to the baseline. Conclusion: Saroglitazar treatment is effective and there is a significant difference in Serum alanine aminotransferase and aspartate aminotransferase, triglycerides and Liver Stiffness Measurement levels after treatment. The drug can be successfully administered for the treatment of Non-alcoholic fatty liver disease.

show abstract

Diabetes Mellitus, Nonalcoholic Fatty Liver Disease, and Conjugated Linoleic Acid (Omega 6): What Is the Link?

Cited by 20 publications

References 40 publications

Potential New Biomarkers Discovery of Early Nonalcoholic Fatty Liver Disease in Human by Liquid Chromatography–Mass Spectrometry

Potential New Biomarkers Discovery of Early Nonalcoholic Fatty Liver Disease in Human by Liquid Chromatography–Mass Spectrometry

Conjugated Linoleic Acid Treatment Attenuates Cancerous features in Hepatocellular Carcinoma Cells

An Investigator Initiated Prospective, Single Arm Observational Study to Evaluate the Safety and Efficacy of Saroglitazar 4 mg in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD)/Non- Alcoholic Steatohepatitis (NASH)

Contact Info

Product

Resources

About